DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION						
US Customhous				DATE(S) OF INSPECTION 7/23/2019-8/14/2019*		
Philadelphia	, PA 19106		FEINUMBER 1000221205			
(215) 597-439	Ext:4200 Fax: (2	15) 597-0875		100022	1200	
NAME AND TITLE OF INDIVIDU						
Mark Kaforey	Chief Operating	Officer	STREET ADDRESS			
Xodus Medica						
New Kensingto	on, PA 15068-7052	7052 Manufacturer				
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.						
The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.						
DURING AN INSPECTION OF YOUR FIRM I OBSERVED:  OBSERVATION 1  A validated process was not reviewed and evaluated and revalidated when changes or process deviations occurred.						
Specifically,	Specifically.					
The (b) (4) , used in your production operation (b) (4)						
, does in jour production operation ( )						
On 12/20/2017, maintenance operations were conducted to (b) (4) used for packaging and (b) (4) . You did not review and evaluate, and revalidate your production process for sealing when changes and process deviations occurred.						
OBSERVATION 2 Complaints involving the possible failure of a device, labeling and packaging to meet any of its specifications were not reviewed, evaluated and investigated where necessary.  Specifically,						
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Dennis R Hock, I				Dennis R Hock Investigator Signed By 2000754886 Date Signed 08-14-2019 08 56 24	DATE ISSUED 8/14/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLET	TE INS	PECTIONAL C	BSEKVATI	ONS	PAGE 1 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION						
DISTRICT ADDRESS AND PHO	ne number se Rm900 200 Chestnut St	DATE(S) OF INSPECTION 7/23/2019-8/14/2019*				
Philadelphia		FEI NUMBER 1000221				
NAME AND TITLE OF INDIVIDU						
Mark Kaforey	, Chief Operating Officer	STREET ADDRESS				
Xodus Medica	l Inc	702 Promi	inence D	r		
New Kensingto	on, PA 15068-7052	Manufacti				
and packaging to	Returned Goods Authorizations (RGA), documenting information involving possible failure of a device, labeling and packaging to meet any of its specifications were not reviewed, evaluated and investigated where necessary. Additionally, the RGA's are not all shared or provided to the department responsible for evaluating complaints.					
Production prod	OBSERVATION 3 Production processes were not conducted, controlled and monitored to ensure that a device conforms to its specifications.					
Specifically,						
(b) (4)	maintenance operations were conducted used in your ted after maintenance.	to (b) (4) production	process. T	used for pack he (b) (4)	kaging and	
		(4)				
On the following dates, you received complaints for (b) (4) surgical devices:						
8/28/2018	Complaint #651 Insufficient Heat Seal					
12/04/2018	4/2018 Complaint #663 Insufficient Heat Seal					
1/22/2019	Complaint #668 Insufficient Heat Seal					
5/07/2019	Complaint #681 Insufficient Heat Seal					
6/20/2019	Complaint #685Insufficient Heat Seal					
In addition, you received Returned Goods Authorizations (RGA's) for (b) (4) surgical devices that were not documented as complaints.						
6/12/2017 RGA #692 Documents "various" lots						
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE  Dennis R Hock, Investigator			Dennis R Hook investigator Signed By 2000754886 Date Signed 09-14-2019 08 56 24	8/14/2019	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	PECTIONAL O	BSERVATIO	ONS	PAGE 2 of 5 PAGES	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER  US Customhouse Rm900 200 Chestnut St	DATE(S) OF INSPECTION 7/23/2019-8/14/2019*				
Philadelphia, PA 19106 (215)597-4390 Ext:4200 Fax:(215)597-0875	FEI NUMBER 1000221205				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Mark Kaforey, Chief Operating Officer					
FIRM NAME	STREET ADDRESS				
Xodus Medical Inc	702 Prominence Dr				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
New Kensington, PA 15068-7052	Manufacturer				

6/16/2017 RGA #686 Lot #15NOV03A 3/07/2018 RGA #778 Lot #17DEC08

Your production processes were not conducted, controlled and monitored to ensure that a device conforms to its specifications.

## **OBSERVATION 4**

Products that do not conform to specifications are not adequately controlled.

Specifically,

The (b) (4) , used in your production operations to (b) (4) surgical device, (b) (4) Lots manufactured between 12/19/2016 and 12/20/2017, were not inspected to determine conformance. These Lots were subsequently released and distributed.

## **OBSERVATION 5**

Complaint files are not maintained.

Specifically,

Between 11/01/2016 through 7/25/2019, you received 452 Returned Goods Authorizations (RGA) for all products manufactured. These RGA's are not all shared or provided to the department responsible for evaluating complaints. As such, the RGA's were not reviewed and evaluated to determine if the reported failures required documenting a complaint.

## **OBSERVATION 6**

Corrective and preventive action activities and/or results have not been documented.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE  Dennis R Hock, Investigat	or	Dennils R Hook Investigation Signed by 2000754886 Date slighted 08-14-2019 08 56 24	DATE ISSUED 8/14/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 3 of 5 PAGES

	DEPARTMENT OF HEAL FOOD AND DRU	TH AND HUMA G ADMINISTRATI		ES		
	ADDRESS AND PHONE NUMBER			DATE(S) OF INSPECTION		
Philadelphia	se Rm900 200 Chestnut St		7/23/2019-8/14/2019* FEI NUMBER			
	0 Ext:4200 Fax:(215)597-0875		1000221205			
NAME AND TITLE OF INDIVIDUA	N. TO WHOM DEPORT ISSUED					
	, Chief Operating Officer					
FIRM NAME	, chief operating officer	STREET ADDRESS				
Xodus Medical	l Inc	702 Prominence Dr				
CITY, STATE, ZIP CODE, COUN		TYPE ESTABLISHME				
New Kensingto	on, PA 15068-7052	Manufacturer				
and/or results.  OBSERVATION Procedures for respectifically, During manufact non-conforming disposition. You  *DATES OF I	uring you (b) (4) products from their failed packaging do not have established procedures for NSPECTION, 7/25/2019(Thu), 7/30/2019(Tue),	ave not been to be (b) (4)	on 12/20/2 ne correcti n establis coduct. It i	2017, after making ve and preventative hed.	to remove these o determining a	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Dennis R Hock, Investigator			Dennis R Hook Investigation Signed By 2000754886 Date Signed 08-14-2019 08 56 24	DATE ISSUED 8/14/2019	
I						

INSPECTIONAL OBSERVATIONS

PAGE 4 of 5 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
US Customhous			DATE(S) OF INSPECTION 7/23/2019-8/14/2019*		
Philadelphia,			FEI NUMBER 1000221205		
NAME AND TITLE OF INDIVIDUAL					
Mark Kaforey,	Chief Operating Officer	STREET ADDRESS			
Xodus Medical		702 Prom	ninence Dr		
	n, PA 15068-7052	Manufact			
Annotations to	Observations				
Observation 1:					
Observation 2:					
Observation 3:					
Observation 4:					
Observation 5:					
Observation 6:					
Observation 7:					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE  Dennis R Hock, Investigato	r	Dennis R Hook Investigator Signed by 2000754886 Dille Signed 08-14-2019 08 56 24	DATE ISSUED 8/14/2019	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE I	NSPECTIONAL (	OBSERVATIONS	PAGE 5 of 5 PAGES	

The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."